Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine
<b>Conclusion:</b> This study provides evidence regarding longer durability of IV-KET compared to IN-ESKET. These findings need to be replicated in larger prospective studies and confirmed in a randomized controlled trial comparing these two treatment interventions.
Authors
- Jennifer L. Vande Voort (ORCID: https://orcid.org/0000-0002-3630-4773)
- Balwinder Singh (ORCID: https://orcid.org/0000-0001-7062-8192)
- Simon Kung (ORCID: https://orcid.org/0000-0002-2959-8312)
- Vanessa Pazdernik (ORCID: https://orcid.org/0000-0001-7566-7334)
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- The Journal of Clinical Psychiatry
- Published
- 2025-07-30
- DOI
- https://doi.org/10.4088/jcp.25m15831
- Citations
- 4
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 5.58